We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI from Patient ECGs Can Detect Cardiovascular Disease Risks Sooner, Suggests Study

By HospiMedica International staff writers
Posted on 26 Oct 2023

Atherosclerotic cardiovascular disease, characterized by arteries that are narrowed or clogged due to fatty deposits, is the number one cause of death worldwide. More...

Often, the condition is driven by coronary artery disease, which many people may have without even knowing it. Tools available to clinicians like the pooled cohort equation are used to evaluate a patient's 10-year risk of heart attacks and strokes, although these methods are not without flaws. Electrocardiograms (ECGs), which record the electrical activity of the heart, are commonly used tests. Artificial intelligence (AI) has the ability to recognize and analyze hidden disease patterns in these electrical signals. Now, a new study suggests that AI applied to patient ECGs could offer a more efficient way to assess the risk of heart disease.

According to the research, AI algorithms trained on ECG data can detect potential risks much earlier than existing risk-calculation methods. They can identify symptoms of coronary artery disease like arterial calcification and obstructions, as well as signs of previous heart attacks. The ECG-based AI for evaluating coronary artery disease risk was jointly created by at Mayo Clinic (Rochester, MN, USA) and Anumana, Inc. (Cambridge, MA, USA) using a retrospective analysis of electronic medical records from over seven million U.S. patients to train three distinct AI models. These models were designed to spot coronary artery calcium, arterial blockages, and poor movement in segments of the heart's left ventricle, which is an indicator of a past heart attack.

"Used together, the three independent ECG-AI models predicted which patients had a high risk of hidden coronary artery disease, and therefore a high risk of having a heart attack. This is important information to guide our conversations with patients at the point of care, especially since the AI was useful in calculating these risks for as short as three years," said Francisco Lopez-Jimenez, M.D., a cardiologist at Mayo Clinic. "Used alone, the pooled cohort equation estimates the 10-year risk of developing cardiovascular disease. The addition of ECG-AI to see hidden risks sooner has the potential to save more lives. This model may also help identify people who do not know they have coronary disease who may benefit from lifesaving therapies."

Related Links:
Mayo Clinic 
Anumana, Inc. 


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.